This study explored the shared genetic traits and molecular interactions between postmenopausal osteoporosis (POMP) and sarcopenia, both of which substantially degrade elderly health and quality of life. We hypothesized that these motor system diseases overlap in pathophysiology and regulatory mechanisms. We analyzed microarray data from the Gene Expression Omnibus (GEO) database using weighted gene co-expression network analysis (WGCNA), machine learning, and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis to identify common genetic factors between POMP and sarcopenia. Further validation was done via differential gene expression in a new cohort. Single-cell analysis identified high expression cell subsets, with mononuclear macrophages in osteoporosis and muscle stem cells in sarcopenia, among others. A competitive endogenous RNA network suggested regulatory elements for these genes.Aims
Methods
Plots are an elegant and effective way to represent
data. At their best they encourage the reader and promote comprehension.
A graphical representation can give a far more intuitive feel to
the pattern of results in the study than a list of numerical data,
or the result of a statistical calculation. The temptation to exaggerate differences or relationships between
variables by using broken axes, overlaid axes, or inconsistent scaling
between plots should be avoided. A plot should be self-explanatory and not complicated. It should
make good use of the available space. The axes should be scaled
appropriately and labelled with an appropriate dimension. Plots are recognised statistical methods of presenting data and
usually require specialised statistical software to create them.
The statistical analysis and methods to generate the plots are as
important as the methodology of the study itself. The software,
including dates and version numbers, as well as statistical tests
should be appropriately referenced. Following some of the guidance provided in this article will
enhance a manuscript. Cite this article:
The ability of mesenchymal stem cells (MSCs)
to differentiate in vitro into chondrocytes, osteocytes
and myocytes holds great promise for tissue engineering. Skeletal
defects are emerging as key targets for treatment using MSCs due
to the high responsiveness of bone to interventions in animal models.
Interest in MSCs has further expanded in recognition of their ability
to release growth factors and to adjust immune responses. Despite their increasing application in clinical trials, the
origin and role of MSCs in the development, repair and regeneration
of organs have remained unclear. Until recently, MSCs could only
be isolated in a process that requires culture in a laboratory;
these cells were being used for tissue engineering without understanding
their native location and function. MSCs isolated in this indirect
way have been used in clinical trials and remain the reference standard
cellular substrate for musculoskeletal engineering. The therapeutic
use of autologous MSCs is currently limited by the need for ex
vivo expansion and by heterogeneity within MSC preparations.
The recent discovery that the walls of blood vessels harbour native
precursors of MSCs has led to their prospective identification and isolation.
MSCs may therefore now be purified from dispensable tissues such
as lipo-aspirate and returned for clinical use in sufficient quantity,
negating the requirement for ex vivo expansion
and a second surgical procedure. In this
